British HIV Association guidelines for immunization of HIV-infected adults 2008

HIV Medicine

Volumn 9, Issue 10, 2008, Pages 795-848

  Geretti, A M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

CD4 cell count; HIV; Immunoglobulin; Travel; Vaccine

Indexed keywords

ANTHRAX VACCINE; ANTIVIRUS AGENT; BCG VACCINE; CHOLERA VACCINE; CIPROFLOXACIN; DIPHTHERIA VACCINE; FSME IMMUN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HUMAN IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RIFAMPICIN; SMALLPOX VACCINE; STEROID; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; ARTHRALGIA; ARTHRITIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BRAIN DISEASE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CHILL; CHOLERA; CLINICAL TRIAL; DIPHTHERIA; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECZEMA; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; FATIGUE; FLU LIKE SYNDROME; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE TYPE B; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION RISK; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; INJECTION SITE ULCER; INSOMNIA; IRRITABILITY; LYMPHADENITIS; LYMPHADENOPATHY; MALAISE; MEASLES; MENINGOCOCCOSIS; MONOTHERAPY; MUMPS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROTROPIC DISEASE; NONHUMAN; OSTEITIS; OSTEOMYELITIS; PAROTITIS; PERICARDITIS; PERTUSSIS; PNEUMONIA; POLIOMYELITIS; POSTVACCINAL ENCEPHALITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RABIES; RECOMMENDED DRUG DOSE; REVACCINATION; REVIEW; RISK BENEFIT ANALYSIS; RUBELLA; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SMALLPOX; SORE THROAT; STREPTOCOCCUS INFECTION; SWEATING; SYSTEMIC DISEASE; TETANUS; THROMBOCYTOPENIA; TICK BORNE ENCEPHALITIS; TRAVELLER DIARRHEA; TUBERCULOSIS; TYPHOID FEVER; UNITED KINGDOM; URTICARIA; VACCINE FAILURE; VACCINIA; VISCEROTROPIC DISEASE; VOMITING; YELLOW FEVER;

ADULT; AIDS VACCINES; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; MALE; VACCINATION; VACCINES;

EID: 55649116225     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00637.x     Document Type: Review

References (278)

1. Salisbury D, Ramsay M, Noakes K. eds. Immunization Against Infectious Disease (The Green Book). London, Department of Health, Scottish Executive, Welsh Assembly Government, Department of Health, Social Services and Public Safety, 2006. Available at http://www.dh.gov.uk/en/ Policyandguidance/Healthandsocialcaretopics/Greenbook/DH_4097254.
2. Kolber MA, Gabr AH, De La Rosa A et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS 2002; 16: 537-542.
3. Lee PD, Kieffer TL, Siciliano RF, Nettles RE. HIV-1 viral load blips are of limited clinical significance. Antimicrob Chemother 2006; 57: 803-805.
4. Enstone JE, Wale MC, Nguyen-Van-Tam JS, Pearson JC. Adverse medical events in British service personnel following anthrax vaccination. Vaccine 2003; 21: 1348-1354.
5. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363: 223-233.
6. Legros D, Paquet C, Perea W et al. Mass vaccination with a 2-dose oral cholera vaccine in a refugee camp. Bull World Health Organ 1999; 77: 837-842.
7. von Seidlein L, Wang XY, Macuamule A et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. Trop Med Int Health 2008; 13: 683-688.
8. Holmgren J, Bergquist J. Oral B subunit-killed whole-cell cholera vaccine, In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF. eds. New Generation Vaccines. New York, Marcel Dekker, 2004: 499-509.
9. Jertborn M, Svennerholm AM, Holmgren J. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1993; 11: 1007-1012.
10. Sanchez JL, Vasquez B, Begue RE et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994; 344: 1273-1276.
11. Ali M, Emch M, Yunus M et al. Vaccine protection of Bangladeshi infants and young children against cholera: Implications for vaccine deployment and person-to-person transmission. Pediatr Infect Dis J 2008; 27: 33-37.
12. Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: Use in clinical practice. Lancet Infect Dis 2006; 6: 361-373.
13. Lewis DJ, Gilks CF, Ojoo S et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS 1994; 8: 779-785.
14. Health Protection Agency. Diphtheria notifications. Laboratory isolates of Corynebacterium diphtheriae, deaths and vaccine uptake rates. Available at http://www.hpa.org.uk/infections/topics_az/diphtheria/ data_death_vaccine.htm.
15. Myers MG, Beckman CW, Vosingh RA, Hankins WA. Primary immunisation with tetanus and diphtheria toxoids: Reaction rates and immunogenicity in older children and adults. JAMA 1982; 248: 2478-2480.
16. Galazka AM, Robertson SE. Immunisation against diphtheria with special emphasis on immunization of adults. Vaccine 1996; 14: 845-857.
17. Poland GA, Love KR, Hughes CE. Routine immunizations in the HIV-positive asymptomatic patient. J Gen Inter Med 1990; 5: 147-152.
18. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998; 11: 1-26.
19. Kroon FP, Van Dissel JT, Labadie J, Van Loon AM, Van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4 T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1197-1203.
20. Janoff EN, Hardy WD, Smith PD, Wahl SM. Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991; 147: 2130-2135.
21. Bonetti TC, Succi RC, Weckx LY, Tavares-Lopes L, Moraes-Pinto MI. Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004; 22: 3707-3712.
22. Valdez H, Smith KY, Landay A et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS 2000; 14: 11-21.
23. Bonnet JM, Begg NT. Control of diphtheria: Guidance for consultants in communicable disease control. Commun Dis Public Health 1999; 2: 242-249.
24. Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 1992; 268: 3350-3352.
25. Casadevall A, Dobroszycki J, Small C, Pirofski LA. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 1992; 92: 587-590.
26. Steinhoff MC, Auerbach BS, Nelson KE et al. Antibody responses to Haemophilus influenzae type b vaccines in men with human immunodeficiency virus infection. N Engl J Med 1991; 325: 1837-1842.
27. Madhi SA, Cumin E, Klugman KP. Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatr Infect Dis J 2002; 21: 393-399.
28. Madhi SA, Petersen K, Khoosal M et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21: 315-321.
29. Dockrell DH, Poland GA, Steckelberg JM, Wollan PC, Strickland SR, Pomeroy C. Immunogenicity of 3 Haemophilus influenzae type b protein conjugate vaccines in HIV-seropositive adults and analysis of predictors of vaccine response. Vaccine 1999; 17: 2779-2785.
30. Weiss PJ, Wallace MR, Oldfield EC III, O'Brien J, Janoff EN. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995; 171: 1217-1222.
31. De Sousa dos SS, Lopes MH, Simonsen V, Caiaffa Filho HH. Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 2004; 20: 493-496.
32. Cotter SM, Sansom S, Long T et al. Outbreak of hepatitis A among men who have sex with men: Implications for hepatitis A vaccination strategies. J Infect Dis 2003; 187: 1235-1240.
33. Bianco E, Stroffolini T, Spada E et al. Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. Dig Liver Dis 2003; 35: 404-408.
34. Willner IR, Uhl MD, Howard SC et al. Serious hepatitis A: An analysis of patients hospitalised during an urban epidemic in the United States. Ann Int Med 1998; 128: 111-114.
35. Fonquernie L, Meynard JL, Charrois A, Delamare C, Meyohas MC, Frottier J. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 32: 297-299.
36. Ida S, Tachikawa N, Nakajima A et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002; 34: 379-385.
37. Costa-Mattioli M, Allavena C, Poirier AS, Billaudel S, Raffi F, Ferre V. Prolonged hepatitis A infection in an HIV-1-seropositive patient. J Med Virol 2002; 68: 7-11.
38. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and uninfected homosexual men. J Infect Dis 1997; 176: 1064-1067.
39. Wallace MR, Brandt CJ, Earhart KC et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39: 1207-1213.
40. Kemper CA, Haubrich R, Frank I et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: A double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187: 1327-1331.
41. Weinberg A, Gona P, Nachman SA et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193: 302-311.
42. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005; 19: 1702-1704.
43. Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: A hierarchical Bayesian meta-analysis. Vaccine 2006; 24: 272-279.
44. Hess G, Clemens R, Bienzle U, Schonfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40-42.
45. Tilzey AJ, Palmer SJ, Harrington C, O'Doherty MJ. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996; 14: 1039-1041.
46. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006; 13: 81-86.
47. Colin JF, Cazals-Hatem D, Loriot MA et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatol 1999; 29: 1306-1310.
48. Rockstroh J, Konopnicki D, Soriano V et al. Hepatitis B and hepatitis C in the EuroSIDA Cohort: Prevalence and effect on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 799].
49. Wong KL, Bodsworth NJ, Slade MA et al. Response to hepatitis B vaccination in a primary care setting: Influence of HIV infection, CD4 lymphocyte count and vaccination schedule. Int J STD AIDS 1996; 7: 490-494.
50. Rey D, Krantz V, Partisani M et al. Increasing the number of hepatitis B injections augments anti-HBs response rate in HIV-infected patients. Effect on viral load. Vaccine 2000; 18: 1161-1165.
51. Nothdurft HD, Dietrich M, Zuckerman JN et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002; 20: 1157-1162.
52. Rubinstein L, King G, Brook MG. Does hepatitis B ultra-rapid vaccination work in HIV-positive people? A comparative study of HIV-positive and HIV-negative vaccine recipients. 11th Annual Conference of the British HIV Association with the British Association for Sexual Health and HIV. Dublin Ireland, April 2005 [Abstract P97].
53. Francis DP, Hadler SC, Thompson SE et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center trial among homosexual men. Ann Int Med 1982; 97: 362-366.
54. Jack AD, Hall AJ, Maine N et al. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179: 489-492.
55. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
56. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve year follow-up of a prospective randomized trial of recombinant DNA yeast vaccine vs. plasma-derived vaccine without booster doses in children. Hepatology 1999; 29: 924-927.
57. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: Results of a 10-year study. J Infect Dis 1997; 175: 674-677.
58. Clemens R, Sanger R, Kruppenbacher J et al. Booster immunisation of low- and non-responders after a standard 3-dose hepatitis B vaccine schedule - results of post-marketing surveillance. Vaccine 1997; 15: 349-352.
59. Goldwater PN. Randomized, comparative trial of 20 micrograms vs. 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15: 353-356.
60. Biggar RJ, Goedert JJ, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987; 316: 630-631.
61. Odaka N, Eldred L, Cohn S et al. Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA 1988; 260: 3635-3637.
62. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109: 101-105.
63. Loke RH, Murray-Lyon IM, Coleman JC, Evans BA, Zuckerman AJ. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: An indicator of poor prognosis. J Med Virol 1990; 31: 109-111.
64. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994; 8: 558-559.
65. Wilson CM, Ellenberg JH, Sawyer MK et al. Serologic response to hepatitis B vaccine in HIV-infected and high-risk HIV uninfected adolescents in the REACH Cohort. J Adolesc Health 2001; 29 (Suppl. 3): 123-129.
66. Veiga APR, Casseb J, Duarte AJS. Humoral response to hepatitis B vaccination and its relationship with T CD45RA (naïve) and CD45RO (memory) subsets in HIV-1-infected subjects. Vaccine 2006; 24: 7124-7128.
67. Tedaldi EM, Baker RK, Moorman AC et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38: 1478-1484.
68. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-2908.
69. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577.
70. de Vries-Sluijs TE, Hansen BE, van Doornum GJ et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008; 197: 292-294.
71. Filion LG, Saginur R. Induction of the in vitro anti-HBs response by hepatitis B surface antigen. Clin Exp Immunol 1988; 74: 321-325.
72. Hadler SC, Judson FN, O'Malley PM et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454-459.
73. Gandhi RT, Wurcel A, Lee H et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: Implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191: 1435-1441.
74. Nebbia G, Garcia-Diaz A, Ayliffe U et al. Predictors and kinetics of occult hepatitis B virus (HBV) infection in HIV-infected persons. J Med Virol 2007; 79: 1464-1471.
75. Palmovic D, Crnjakovic-Palmovic J. Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: A comparison of 2 prophylactic schedules. Infection 1993; 2: 42-45.
76. Winsnes R, Siebke JC. Efficacy of post-exposure prophylaxis with hepatitis B immunoglobulin in Norway. J Infect 1986; 12: 11-21.
77. Cohen JP, Macauley C. Susceptibility to influenza A in HIV-positive patients. JAMA 1989; 261: 245.
78. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990; 98: 33-37.
79. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281: 901-907.
80. Fine AD, Bridges CB, De Guzman AM et al. Influenza A among patients with human immunodeficiency virus: An outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001; 32: 1784-1791.
81. Radwan HM, Cheeseman SH, Lai KK, Ellison RT III. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31: 604-606.
82. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161: 441-446.
83. Kroon FP, van Dissel JT, De Jong JC, Furth RV. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4 lymphocytes. AIDS 1994; 8: 469-476.
84. Huang KL, Ruben FL, Rinaldo CR Jr, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987; 257: 2047-2050.
85. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a 2-dose regimen of influenza vaccine. JAMA 1989; 262: 779-783.
86. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: A randomized, double-blind, placebo-controlled study. J Infect Dis 1996; 174: 1332-1336.
87. Iorio AM, Alatri A, Francisci D et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine 1997; 15: 97-102.
88. Fowke KR, D'Amico R, Chernoff DN et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997; 11: 1013-1021.
89. Tasker SA, O'Brien WA, Treanor JJ et al. Effects of influenza vaccination in HIV-infected adults: A double-blind, placebo-controlled trial. Vaccine 1998; 16: 1039-1042.
90. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28: 541-547.
91. Couch RB. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999; 28: 548-551.
92. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: A consecutive 3-year study. Vaccine 2000; 18: 3040-3049.
93. Amendola A, Boschini A, Colzani D et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001; 65: 644-648.
94. Iorio AM, Francisci D, Camilloni B et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003; 21: 3629-3637.
95. Kroon FP, Rimmelzwaan GF, Roos MT et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12: F217-223.
96. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 430-433.
97. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: A systematic review and meta-analysis. HIV Med 2008; 9: 57-61.
98. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20 (Suppl. 5): B29-32.
99. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 1993; 42: 1-15.
100. Rojanasuphot S, Shaffer N, Chotpitayasunondh T et al. Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1998; 29: 443-450.
101. World Health Organization. Japanese encephalitis vaccines. Available at http://www.who.int/docstore/wer/pdf/1998/wer7344.pdf
102. Pancharoen C, Ananworanich J, Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Curr HIV Res 2004; 2: 293-299.
103. Wilson ME, von Reyn CF, Fineberg HV. Infections in HIV-infected travellers: Risks and prevention. Ann Intern Med 1991; 114: 582-592.
104. Kidd IM, Booth CJ, Rigden SPA, Tong WCY, MacMahon EM. Measles-associated encephalitis in children with renal transplants: A predictable effect of waning herd immunity? Lancet 2003; 263: 832.
105. Health Protection Agency. Press statement 4 February 2005. Available at http://www.hpa.org.uk/hpa/news/articles/press_releases/2005/ 050204_mumps.htm
106. Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science 2003; 301: 804.
107. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267: 1237-1241.
108. Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of 2 cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993; 16: 654-660.
109. Kemper CA, Gangar M, Arias G, Kane C, Deresinski SC. The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California. J Infect Dis 1998; 178: 1177-1180.
110. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11: 1008-1014.
111. Thomas HI, Aird HC. Maintenance of high-avidity rubella-specific IgG antibody and titres in recent HIV seroconverters and in patients progressing to the AIDS-related complex and AIDS. J Med Virol 1999; 58: 273-279.
112. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a 2-dose MMR vaccination. A nine-year follow-up. Vaccine 1995; 13: 1617-1622.
113. Sprauer MA, Markowitz LE, Nicholson JK et al. Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. J Acquir Immune Defic Syndr 1993; 6: 1013-1016.
114. Wallace MR, Hooper DG, Graves SJ, Malone JL. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994; 12: 1222-1224.
115. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human-immunodeficiency virus-infected children. Clin Infect Dis 2001; 32: 1090-1094.
116. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 1998; 47: 1-57.
117. Centers for Disease Control and Prevention. Measles pneumonitis following Measles-Mumps-Rubella vaccination of a patient with HIV infection, 1993. Morbid Mortal Wkly Rep 1996; 45: 603-606. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00043110.htm.
118. Kay HEM, Rankin A. Immunoglobulin prophylaxis of measles in acute lymphblastic leukaemia. Lancet 1984; 1: 901-902.
119. Endo A, Izumi H, Myashita M, Taniguchi K, Okumbo O, Harada K. Current efficacy of postexposure prophylaxis against measles with immunoglobulin. J Pediatrics 2001; 138: 926-928.
120. Health Protection Agency. Immunoglobulin handbook. Indications and dosage for normal and specific immunoglobulin preparations issued by the Health Protection Agency. Available at http://www.hpa.org.uk/infections/ topics_az/immunoglobulin/pdfs/Measles_2007.pdf
121. Kipp W, Kamugisha J, Rehle T. Meningococcal meningitis and HIV infection: Results from a case-control study in western Uganda. AIDS 1992; 6: 1557-1558.
122. Brindle R, Simani P, Newnham R, Waiyaki P, Gilks C. No association between meningococcal disease and human immunodeficiency virus in adults in Nairobi, Kenya. Trans R Soc Trop Med Hyg 1991; 85: 651.
123. Morla N, Guibourdenche M, Riou JY. Neisseria spp. and AIDS. J Clin Microbiol 1992; 30: 2290-2294.
124. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 2005; 54: 1-21.
125. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282: 417-420.
126. Peltola H, Makela H, Kayhty H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children 3 months to 5 years of age. N Engl J Med 1977; 297: 686-691.
127. MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA 2000; 283: 2795-2801.
128. Twumasi PA Jr, Kumah S, Leach A et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171: 632-638.
129. Salisbury D, Miller E, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20 (Suppl. 1): 58-67.
130. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-367.
131. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield RR. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr 1991; 4: 188-196.
132. Rhoads JL, Birx DL, Wright DC et al. Safety and immunogenicity of multiple conventional immunizations administered during early HIV infection. J Acquir Immune Defic Syndr 1991; 4: 724-731.
133. Nitta AT, Douglas JM, Arakere G, Ebens JB. Disseminated meningococcal infection in HIV-seropositive patients. AIDS 1993; 7: 87-90.
134. Health Protection Agency. Notifications, England and Wales, by region, 1991-2004. Available at http://www.hpa.org.uk/infections/topics_az/ whoopingcough/data_not_region.htm
135. Colebunders R, Vael C, Blot K, Van Meerbeeck J, Van den Ende J, Ieven M. Bordetella pertussis as a cause of chronic respiratory infection in an AIDS patient. Eur J Clin Microbiol Infect Dis 1994; 13: 313-315.
136. Doebbeling BN, Feilmeier ML, Herwaldt LA. Pertussis in an adult man infected with the human immunodeficiency virus. J Infect Dis 1990; 161: 1296-1298.
137. Ng VL, York M, Hadley WK. Unexpected isolation of Bordetella pertussis from patients with acquired immunodeficiency syndrome. J Clin Microbiol 1989; 27: 337-338.
138. Cohn SE, Knorr KL, Gilligan PH, Smiley ML, Weber DJ. Pertussis is rare in human immunodeficiency virus disease. Am Rev Respir Dis 1993; 147: 411-413.
139. Halperin SA, Smith B, Russell M et al. An adult formulation of a 5-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000; 18: 1312-1319.
140. Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 2005; 23: 3829-3835.
141. De Martino M, Podda A, Galli L et al. A cellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine 1997; 15: 1235-1238.
142. Dodhia H, Crowcroft NS, Bramley JC, Miller E. UK guidelines for the use of erythromycin chemoprophylaxis in persons exposed to pertussis. J Public Health Med 2002; 24: 200-206.
143. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 1997; 46: 1-24.
144. Keller DW, Breiman RF. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (Suppl. 1): 77-83.
145. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32: 794-800.
146. Breiman RF, Keller DW, Phelan MA et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160: 2633-2638.
147. Gilks CF, Ojoo SA, Ojoo JC et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1-infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347: 718-723.
148. Redd SC, Rutherford GW, Sande MA et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162: 1012-1017.
149. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19: 1141-1147.
150. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132: 182-190.
151. Grau I, Pallares R, Tubau F et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165: 1533-1540.
152. Heffernan RT, Barrett NL, Gallagher KM et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191: 2038-2045.
153. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-2677.
154. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-1348.
155. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005; 40: 1511-1518.
156. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811-813.
157. Ballet J-J, Sulcebe G, Couderc L-J et al. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 1987; 68: 479-487.
158. Rodriguez-Barradas MC, Musher DM, Lahart C et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165: 553-556.
159. Amendola A, Tanzi E, Zappa A et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002; 20: 3720-3724.
160. Janoff EN, Douglas JM Jr, Gabriel M et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis 1988; 158: 983-990.
161. Janoff EN, Fasching C, Ojoo JC, O'Brien J, Gilks CF. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis 1997; 175: 975-978.
162. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: Humoral response and two vaccine failures. AIDS 1998; 12: 1683-1689.
163. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991; 84: 185-189.
164. Rodriguez-Barradas MC, Alexandraki I, Nazir T et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37: 438-447.
165. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: Clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34: 813-821.
166. García-Vázquez E, Yagüe J, Vilella A et al. Antibody responses to capsular polysaccharides of S. pneumoniae after vaccination with the 23-valent pneumococcal polysaccharide vaccine in non-HIV vs. HIV patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract H-1924].
167. Lesprit P, Pedrono G, Molina JM et al. Immunologic efficacy of a prime-boost strategy combining a 7-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide vaccine vs. PPV alone in HIV-infected adults with 200 to 500 CD4 cells/μL. Results of the ANRS 114 Study. 12th Conference on Retrovirus and Opportunistic Infections. Boston, MA, February 2005 [Abstract 140].
168. Lesprit P, Pédrono G, Molina JM et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21: 2425-2434.
169. French N, Nakiyingi J, Carpenter LM et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-2111.
170. Watera C, Nakiyingi J, Miiro G et al. 23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18: 1210-1213.
171. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 857-862.
172. Guerrero M, Kruger S, Saitoh A et al. Pneumonia in HIV-infected patients: A case-control survey of factors involved in risk and prevention. AIDS 1999; 13: 1971-1975.
173. Peñaranda M, Falco V, Payeras A et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: A case-control study. Clin Infect Dis 2007; 45: E82-87.
174. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: A prospective observational study. Vaccine 2004; 22: 2006-2012.
175. Lopez-Palomo C, Martin-Zamorano M, Benitez E et al. Pneumonia in HIV-infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72: 517-524.
176. US Public Health Service (USPHS), Infectious Diseases Society of America (IDSA), USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001; 2: 493-554.
177. Pavlov DN, Van Zyl WB, Kruger M, Blignaut L, Grabow WO, Ehlers MM. Poliovirus vaccine strains detected in stool specimens of immunodeficient children in South Africa. Diagn Microbiol Infect Dis 2006; 54: 23-30.
178. Hennessey KA, Lago H, Diomande F et al. Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire. J Infect Dis 2005; 192: 2124-2128.
179. Ion-Nedelcu N, Dobrescu A, Strebel PM, Sutter RW. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet 1994; 343: 51-52.
180. Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: Case report. Br Med J 1999; 318: 841-843.
181. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. Poliomyelitis. Epidemiology and Prevention of Vaccine-preventable Diseases, 10th edn. Washington DC, Public Health Foundation, Centers for Disease Control and Prevention, 2007. Available at http://www.cdc.gov/vaccines/pubs/pinkbook/ downloads/polio.pdf
182. Barbi M, Bardare M, Luraschi C et al. Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV-positive mothers. Eur J Epidemiol 1992; 8: 211-216.
183. Barbi M, Biffi MR, Binda S et al. Immunization in children with HIV seropositivity at birth: Antibody response to polio vaccine and tetanus toxoid. AIDS 1992; 6: 1465-1469.
184. Pregliasco F, Minolfi V, Boschin A, Andreassi A, Profeta ML. A seroepidemiologic survey of immunity against poliomyelitis in a group of HIV-positive and HIV-negative drug addicts. Eur J Epidemiol 1995; 11: 693-695.
185. Vardinon N, Handsher R, Burke M, Zacut V, Yust I. Poliovirus vaccination responses in HIV-infected patients: Correlation with T4 cell counts. J Infect Dis 1990; 162: 238-241.
186. Varon D, Handsher R, Dardik R et al. Response of hemophilic patients to poliovirus vaccination: Correlation with HIV serology and with immunological parameters. J Med Virol 1993; 40: 91-95.
187. Mathisen GE, Allen AD. Inactivated polio vaccine hyperimmunization in adults with HIV disease: A placebo-controlled study. AIDS 1992; 6: 737-751.
188. Srinivasan A, Burton EC, Kuehnert MJ et al. Transmission of rabies virus from an organ donor to 4 transplant recipients. N Engl J Med 2005; 352: 1103-1111.
189. World Health Organization. Rabies infections in organ donor and transplant recipients in Germany. Rabies Bull Eur 2005; 29: 8-9. Available at http://www.who-rabies-bulletin.org/Journal/ Miscellaneous_Articles.aspx?Issue=2005_3.
190. Willoughby RE Jr, Tieves KS, Hoffman GM et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352: 2508-2514.
191. World Health Organization. Rabies. Available at http://www.who.int/ rabies/
192. Knobel DL, Cleaveland S, Coleman PG et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83: 360-368.
193. Cliquet F, Picard-Meyer E. Rabies and rabies-related viruses: A modern perspective on an ancient disease. Rev Sci Tech 2004; 23: 625-642.
194. Fooks AR, Brookes SM, Healy D et al. Detection of antibodies to EBLV-2 in Daubenton's bats in the UK. Vet Rec 2004; 154: 245-246.
195. World Health Organization. Recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. Available at http://whqlibdoc.who.int/hq/1996/ WHO_EMC_ZOO_96.6.pdf
196. World Health Organization. Expert consultation on rabies. WHO Technical report series 931 first report. Available at http://www.wpro.who.int/NR/ rdonlyres/B1ED8443-0993-408C-BF09-D1D06A6E1B45/0/ FINALTEXTWHOTechnicalReportSeries090605.pdf
197. Thisyakorn U, Pancharoen C, Ruxrungtham K et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 2000; 30: 218.
198. Thisyakorn U, Pancharoen C, Wilde H. Immunologic and virologic evaluation of HIV-1-infected children after rabies vaccination. Vaccine 2001; 8: 1534-1537.
199. Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4 T lymphocyte counts. Clin Infect Dis 2001; 33: E122-E124.
200. Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis 1999; 28: 913-914.
201. Dobardzic A, Izurieta H, Woo EJ et al. Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 2007; 25: 4244-4251.
202. World Health Organization. Smallpox. Available at http://www.who.int/ mediacentre/factsheets/smallpox/en/
203. Centers for Disease Control and Prevention. Smallpox. Available at http://www.bt.cdc.gov/agent/smallpox/response-plan/files/ guide-b-part2of3.pdf
204. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316: 673-676.
205. Tasker SA, Schnepf GA, Lim M et al. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis 2004; 38: 1320-1322.
206. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960; 26: 176-189.
207. Freed ER, Duma RJ, Escobar MR. Vaccinia necrosum and its relationship to impaired immunologic responsiveness. Am J Med 1972; 52: 411-420.
208. Turkel SB, Overturf GD. Vaccinia necrosum complicating immunoblastic sarcoma. Cancer 1977; 40: 226-233.
209. Simonsen O, Bentzon MW, Kjeldsen K et al. Evaluation of vaccination requirements to secure continuous antitoxin immunity to tetanus. Vaccine 1987; 5: 115-122.
210. McCarrol JR, Abrahams I, Skudder PA. Antibody response to tetanus toxoid 15 years after initial immunisation. Am J Public Health 1962; 52: 1669-1675.
211. Ambrosino DM, Molrine DC. Critical appraisal of immunization strategies for prevention of infection in the compromised host. Hematol Oncol Clin North Am 1993; 7: 1027-1050.
212. Dieye TN, Sow PS, Simonart T et al. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine 2001; 20: 905-913.
213. Rosenblatt HM, Song LY, Nachman SA et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005; 116: 698-703.
214. Borkowsky W, Steele CJ, Grubman S, Moore T, La Russa P, Krasinski K. Antibody responses to bacterial toxoids in children infected with human immunodeficiency virus. J Pediatr 1987; 110: 563-566.
215. McComb JA. The prophylactic dose of homologous antitoxin. N Eng J Med 1963; 270: 175-178.
216. Panasiuk B, Prokopowicz D, Panasiuk A. Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection 2003; 31: 45-46.
217. Wolf HM, Pum M, Jager R, Istvan L, Mannhalter JW, Eibl MM. Cellular and humoral immune responses in haemophiliacs after vaccination against tick-borne encephalitis. British J Haematol 1992; 82: 374-383.
218. World Health Organization. Typhoid vaccines. Weekly Epidemiological Record 2000; 75: 257-264. Available at http://www.who.int/docstore/wer/ pdf/2000/wer7532.pdf
219. Centers for Disease Control and Prevention. Typhoid immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 1994; 43: 1-7.
220. Gotuzzo E, Frisancho O, Sanchez J et al. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area. Arch Intern Med 1991; 151: 381-382.
221. Wolday D, Erge W. Antimicrobial sensitivity pattern of salmonella: comparison of isolates from HIV-infected and HIV-uninfected patients. Trop Doct 1998; 28: 139-141.
222. Khan M, Coovadia Y, Sturm AW. Typhoid fever and asymptomatic human immunodeficiency virus infection. A report of 10 cases. J Clin Gastroenterol 1997; 25: 507-512.
223. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12: 195-199.
224. Ambrosch F, Fritzell B, Gregor J et al. Combined vaccination against yellow fever and typhoid fever: A comparative trial. Vaccine 1994; 12: 625-628.
225. Acharya IL, Lowe CU, Thapa R et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 1987; 317: 1101-1104.
226. Klugman KP, Gilbertson IT, Koornhof HJ et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 330: 1165-1169.
227. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine 3 years after immunization. Vaccine 1996; 14: 435-438.
228. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 329: 1049-1052.
229. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989; 8: 374-381.
230. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336: 891-894.
231. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of 2, 3, or 4 doses of TY21a live oral typhoid vaccine in enteric-coated capsules: A field trial in an endemic area. J Infect Dis 1989; 159: 766-769.
232. Simanjuntak CH, Paleologo FP, Punjabi NH et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338: 1055-1059.
233. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: 3-year results. J Infect Dis 1982; 145: 292-295.
234. Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 1998, Issue 4. Art. No.: CD001261.
235. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine 1999; 17: 2941-2945.
236. Advisory Council for the Elimination of Tuberculosis (ACET). The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. Morbid Mortal Wkly Rep 1996; 45: 1-18.
237. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: A meta-analysis. Int J Epidemiol 1993; 22: 1154-1158.
238. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
239. Ninane J, Grymonprez A, Burtonboy G, Francois A, Cornu G. Disseminated BCG in HIV infection. Arch Dis Child 1988; 63: 1268-1269.
240. Centers for Disease Control and Prevention. Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. Morbid Mortal Wkly Rep 1985; 34: 227-228.
241. von Reyn CF, Clements CJ, Mann JM. Human immunodeficiency virus infection and routine childhood immunisation. Lancet 1987; 2: 669-672.
242. Lumb R, Shaw D. Mycobacterium bovis (BCG) vaccination: Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus. Med J Aust 1992; 156: 286-287.
243. Boudes P, Sobel A, Deforges L, Leblic E. Disseminated Mycobacterium bovis infection from BCG vaccination and HIV infection. JAMA 1989; 262: 2386.
244. Smith E, Thybo S, Bennedsen J. Infection with Mycobacterium bovis in a patient with AIDS: A late complication of BCG vaccination. Scand J Infect Dis 1992; 24: 109-110.
245. Reynes J, Perez C, Lamaury I, Janbon F, Bertrand A. Bacille Calmette-Guerin adenitis 30 years after immunization in a patient with AIDS. J Infect Dis 1989; 160: 727.
246. Armbruster C, Junker W, Vetter N, Jaksch G. Disseminated Bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 1990; 162: 1216.
247. Colebunders RL, Lebughe I, Musampu M, Pauwels P, Francis H, Ryder R. BCG vaccine abscesses are unrelated to HIV infection. JAMA 1988; 259: 352.
248. Lallemant-Le Coeur S, Lallemant M, Cheynier D, Nzingoula S, Drucker J, Larouze B. Bacillus Calmette-Guerin immunization in infants born to HIV-1-seropositive mothers. AIDS 1991; 5: 195-199.
249. Vyse AJ, Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults. Epidemiol Infect 2004; 132: 1129-1134.
250. Garnett GP, Cox MJ, Bundy DAP, Didier JM, St Catharine J. The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiol Infect 1993; 110: 361-372.
251. Perronne C, Lazanas M, Leport C et al. Varicella in patients infected with the human immunodeficiency virus. Arch Dermatol 1990; 126: 1033-1036.
252. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003; 70 (Suppl. 1): 9-14.
253. Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes 2001; 8: 32-36.
254. Tangsinmankong N, Kamchaisatian W, Lugan-Zilbermann J et al. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol 2004; 113: 742-746.
255. Saiman L, LaRussa P, Steinberg SP et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol 2001; 22: 279-283.
256. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
257. Levin MJ, Gershon AA, Weinberg A et al. Immunization of HIV-infected children with varicella vaccine. J Pediatrics 2001; 139: 305-310.
258. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 2007; 56: 1-40.
259. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4 T cells. J Infect Dis 2006; 194: 247-255.
260. Brady K, Weinberg A, Lacy K, Levin M, Smith G, MacGregor RR. Safety and immune response of varicella vaccine in HIVinfected adults with a history of immune compromise and prior infection with varicella. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 773].
261. Centers for Disease Control and Prevention. ACIP provisional recommendations for prevention of varicella. Available at http://www.cdc.gov/vaccines/vpd-vac/varicella/downloads/ varicella-acip-recs-prov-june-2006.pdf
262. Vázquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005; 352: 439-440.
263. Breuer J. Varicella vaccination for healthcare workers. Br Med J 2005; 330: 433-434.
264. Gershon AA. Varicella vaccine: Rare serious problems - but the benefits still outweigh the risks. J Infect Dis 2003; 188: 945-947.
265. Medicines Compendium. SPC entry for Sanofi Pasteur MSD Limited Varivax. Available at http://emc.medicines.org.uk
266. Ferson MJ. Varicella vaccine in post-exposure prophylaxis. Commun Dis Intell 2001; 25: 13-15.
267. Evans EB, Pollock TM, Cradock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980; 1: 354-356.
268. Asano Y, Yoshikawa T, Suga S et al. Post exposure prophylaxis of varicella in family contacts by acyclovir. Pediatrics 1993; 92: 219-222.
269. Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69: 639-642.
270. Monath TP. Yellow fever: An update. Lancet Infectious Diseases 2001; 1: 11-20.
271. Centers for Disease Control and Prevention. Traveler's health: Yellow book. Available at http://www2.ncid.cdc.gov/travel/yb/utils/ ybGet.asp?section=dis&obj=yellowfever.htm
272. Sibailly TS, Wiktor SZ, Tsai TF et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997; 16: 1177-1179.
273. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 2000; 31: E7-E8.
274. Tattevin P, Depatureaux AG, Chapplain JM et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004; 18: 825-827.
275. Khromava AY, Eidex RB, Weld LH et al. The Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23: 3256-3263.
276. Martin M, Weld LH, Tsai TF et al. Sentinel Yellow Fever Working Group. Advanced age as risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7: 945-951.
277. Centers for Disease Control and Prevention. Yellow fever vaccination: recommendations of the Advisory Committee on Immunisation Practices (ACIP). Morbid Mortal Wkly Rep 2002; 51: 1-11.
278. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85: 131-149.